Zhi-Wei Liang

32PUBLICATIONS
52CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 03, 2026
BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

|Aug 12, 2026
Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial.

|Apr 30, 2026
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

|Apr 22, 2026
Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

|Apr 14, 2026
Adverse Effects of Low Serum HDL-C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia.

Weiran Lv, Shutong Liu, Jiangtao Song

|Mar 25, 2026
FLT3-ITD scaffolds PKCι-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML.

Yun Wang, Shuzhao Chen, Shutong Liu

Pageof 6

Frequent Collaborators

7 joint publications

Robert Peter Gale

6 joint publications

Weida Wang

3 joint publications

Xiaojun Huang

3 joint publications

Zhongjun Xia